Phase I trial of anti-CD3-stimulated CD4+ T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced cancer

Journal of Clinical Oncology

Volumn 16, Issue 8, 1998, Pages 2752-2760

  Curti, Brendan D ^a   Ochoa, Augusto C ^b   Powers, Gerry C ^b   Kopp, William C ^b   Alvord, W Gregory ^b   Janik, John E ^b   Gause, Barry L ^b   Dunn, Barbara ^b   Kopreski, Michael S ^b   Fenton, Robert ^b   Zea, Arnold ^b   Dansky Ullmann, Claudio ^b   Strobl, Susan ^b   Harvey, Linda ^b   Nelson, Edward ^b   Sznol, Mario ^b   Longo, Dan L ^b  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

8 QUINOLINOL INDIUM IN 111; CD4 ANTIGEN; CD45 ANTIGEN; CD8 ANTIGEN; CEFADROXIL; CIMETIDINE; CYCLOPHOSPHAMIDE; DOPAMINE; INDOMETACIN; INTERLEUKIN 2; LORAZEPAM; MESNA; METOCLOPRAMIDE; MONOCLONAL ANTIBODY CD3; PARACETAMOL; PETHIDINE; PHENYLEPHRINE; PROCHLORPERAZINE;

ADOPTIVE TRANSFER; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTINUOUS INFUSION; FEMALE; HUMAN; HUMAN CELL; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; LEUKAPHERESIS; MALE; MELANOMA; NAUSEA; NONHODGKIN LYMPHOMA; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECTAL DRUG ADMINISTRATION; SOLID TUMOR; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; VOMITING;

EID: 0031928111     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.8.2752     Document Type: Article

References (26)

1. Tahara H, Lotze MT, Robbins PD, et al: IL-12 gene therapy using direct injection of tumors with genetically engineered autologous fibroblasts. Hum Gene Ther 12:1607-1624, 1995
2. Mazzoni A, Mezzanzanica D, Jung G, et al: CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma. Cancer Res 56:5443-5449, 1996
3. Hsu FJ, Benike C, Fagnoni F, et al: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2:52-58, 1996
4. Loeffler CM, Platt JL, Anderson PM, et al: Antitumor effects of interleukin 2 liposomes and anti-CD3-stimulated T-cells against murine MCA-38 hepatic metastasis. Cancer Res 51:2127-2132, 1991
5. Curti BD, Longo DL, Ochoa AC, et al: Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2. J Clin Oncol 11:652-660, 1993
6. Curti BD, Ochoa AC, Urba WJ, et al: Influence of interleukin-2 regimens on circulating populations of lymphocytes after adoptive transfer of anti-CD3-stimulated T cells: Results from a phase I trial in cancer patients. J Immunother 19:296-308, 1996
7. + T cells plus cyclophosphamide and liposome-encapsulated IL-2 cure murine MC-38 and 3LL tumors and establish tumor-specific immunity. Blood 89:2529-2536, 1997
8. + tumor-infiltrating lymphocytes and peripheral-blood mononuclear cells by direct positive panning on covalently attached monoclonal antibody-coated flasks. J Biol Response Mod 9:463-474, 1990
9. Pockaj BA, Sherry RM, Wei JP, et al: Infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Cancer 73:1731-1737, 1994
10. Sznol M, Clark JW, Smith JW, II, et al: Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma. J Natl Cancer Inst 84:929-937, 1992
11. Crowder MJ, Hand DJ: Analysis of Repeated Measures. New York, NY, Chapman & Hall, 1990
12. Winer BJ, Brown DR, Michels KM: Statistical Principles in Experimental Design. New York, NY, McGraw-Hill, 1991
13. Rosenberg SA, Yannelli JR, Yang JC, et al: Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 86:1159-1166, 1994
14. Topalian SL, Solomon D, Avis FP, et al: Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recoinbinant interleukin-2: A pilot study. J Clin Oncol 6:839-853, 1988
15. Rosenberg SA: Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 4:175-182, 1997
16. Abrams SI, Hodge JW, McLaughlin JP, et al: Adoptive immunotherapy as an in vivo model to explore antitumor mechanisms induced by a recombinant anticancer vaccine. J Immunother 20:48-59, 1997
17. Chang AE, Aruga A, Cameron MJ, et al: Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. J Clin Oncol 15:796-807, 1997
18. + T lymphocytes infiltrating human breast cancer recognise autologous tumor in an MHC-class-II restricted fashion. Cancer Immunol Immunother 40:1-9, 1995
19. + cytotoxic T lymphocytes stimulated by immobilized anti-CD3 monoclonal antibody and interleukin-2 in cancer patients. Int J Cancer 60:802-807, 1995
20. + T lymphocytes against human melanoma. Evidence for a shared melanoma antigen presented by HLA-DR15. J Immunol 154:772-779, 1995
21. Collins RH, Shpilberg O, Drobyski WR, et al: Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 15:433-444, 1997
22. Walter EA, Greenberg PD, Gilbert MJ, et al: Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of t-cell clones from the donor. N Engl J Med 333:1038-1044, 1995
23. Kovacs JA, Baseler M, Dewar RJ, et al: Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. N Engl J Med 332:567-575, 1995
24. Kovacs JA, Vogel S, Albert JM, et al: Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med 335:1350-1356, 1996
25. Zea AH, Curti BD, Longo DL, et al: Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin Cancer Res 1:1327-1335, 1995
26. Mizoguchi H, O'Shea JJ, Longo DL, et al: Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 258:1795-1798, 1992